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Objective: To compare the efficacy of two anticonvulsant drugs topiramate and pregabalin on lumbar radicular 
pain and to find out whether topiramate is a better option or not. 
Study design: Experimental study. 
Place and Duration: This study was conducted at the Department of Neurosurgery, Combined Military Hospital, 
Lahore. The study duration was from January to March 2020. 
Material and Methods: 60 patients of both gender divided into two groups of 30 each were included. Patients 
were assessed based on the subjective impairment scale of the Oswestry Disability Index. The maximum score 
was calculated in percentage with a higher score pointing to greater disability. Both drugs were given in low 
starting once-daily dose, 75 mg for pregabalin, and 25 mg for topiramate for two weeks followed by twice-daily 
dose for two more weeks in patients not getting pain relief.   
Results: Male to female ratio of 4:1 in both groups. The age range of 27-77 years (41.5 + 12.45) for pregabalin and 
22-74 years (41.6 + 14.6) for the topiramate group. Baseline demographics and pre-drug pain measurement index 
were identified amongst the two groups. Oswestry disability index was 49.2 + 18.3 pre-drug and post-drug 41 + 
16.4 for pregabalin (p<0.01). For topiramate, it was 43.6 + 37.9 pre-drug and 37.9 + 17.3 post drug (p <0.01). 
Conclusion: Both pregabalin and topiramate are effective in radicular pain management,  and topiramate is not 
better but still a viable option as an alternative to pregabalin. 
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Introduction 
 
Lumbar radicular pain is defined as the pain radiation 
along with specific nerve roots in the dermatome 
distribution of the lower limb. Amongst the pain 
management drugs, pregabalin is one of the 
commonly used first-line medications.1,2,3 Response to 
pain management is different for every individual 
hence treatment has to be tailored accordingly. 
Pregabalin is also widely used as a treatment for 
epilepsy, neuropathic pain, fibromyalgia, restless leg 
syndrome, and generalized anxiety disorder.4 It was 
developed as a successor to gabapentin. Common side 
effects include headache, dizziness, confusion, 
memory lapse, poor coordination, peripheral edema, 
dry mouth, blurring of vision, and weight gain. 
Serious side effects include angioedema, drug misuse, 
associate degreed a multiplied suicide risk.  
Topiramate is an anticonvulsant and is used to 
manage painful neuropathies including diabetic 
neuropathy and trigeminal neuralgia.5,6 It has also 
been used in chronic lumbar radicular pain.7 Its 
mechanism of action is by augmenting the  
aminobutyric acid activity and modulation of voltage-
dependent sodium channels to block repetitive action 
potentials. There is a suggested mechanism of blocking 
kinate evoked currents through antagonist effect on -
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid 
(AMPA) pathway but not NDMA pathway which is 
the mechanism of action in other antiepileptic drugs. 
Its common side effects are giddiness, somnolence, 
paresthesia, and alter in style, anorexia, weight loss, 
itching, and nervousness. 
 
Materials and Methods 
 
The study was conducted at the Department of 
Neurosurgery, Combined Military Hospital, Lahore 
from January to March 2020. Patients who presented 
with lumbar radiculopathy with degenerative disc 
disease/ nerve root compression on magnetic 
resonance imaging of lumbosacral spine were included 
after getting hospital ethical board review approval to 
vide 143/2019. The sample size was calculated using 
the online “sampsize” calculator sample size 
calculation with a confidence interval of 95%, a margin 
of error of 5%, and a reference prevalence of 4% for 
radicular pain due to disc degenerative spine disease.8 
Patient’s age range from 20 to 70 years of both gender. 
There were 60 patients, with 30 patients who received 
topiramate and 30 patients who were given 
pregabalin.  The sampling technique used was non-
probability convenience sampling Patients who were 
pregnant, undergone lumbar discectomy, received 
epidural steroids in the last 1 month and those with a 
history of diabetes mellitus/psychiatric illness/ 
narrow-angle glaucoma were excluded from the study. 
Topiramate was given at 25 mg every 12 hours for the 
first 2 weeks, followed by 50 mg 12 hourly for further 
two weeks as per pain relief. A control group was 
given Pregabalin 75 mg bed-time titrated to 75 mg 12 
hourly after 2 weeks if required for pain management. 
The effects of both drugs were noticed at the end of 
their trial period of four weeks. A questionnaire was 
filled to score patients based on the Oswestry 
Disability Index. There were 10 questions about the 
effect or limitation on various routine activities and 
employment. Each question had items marked 0 to 5 
(maximum total marks=50). Marks were divided by 50 
and then multiplied with 100 to get a score in 
percentage. The higher the percentage, the more is the 
disability.  The patient’s response was again scored on 
the same questionnaire after 1 month.  Some of the 
patients who did not report for follow-up were 
contacted on the telephone and the questionnaire was 
filled by the investigator. Data was entered and 
analyzed in SPSS version 20. Frequency, mean and 
standard deviation were calculated for quantitative 
variables. An Independent t-test to check the 





The patient’s age range was 27-77 years (41.5 + 12.45) 
for pregabalin and 22-74 years (41.6 + 14.6) for the 
topiramate group of patients with a male to female 
ratio of 4:1 in both groups. Baseline demographics 
were the same for both groups of patients, as given in 
Table 1.  Left-sided sciatica was most common in both 
groups i.e. 28 (46.7%) patients, backache was 
associated with sciatica in 13 (21.7%) patients. Pre-
drug Oswestry Disability Index was 49.2 + 18.3 for the 
pregabalin group and 43.6 + 17.6 in the topiramate 
group. Patients who had a duration of pain for a year 
and more were 19 (63.3%) in the pregabalin group and 
23 (76.6%) in the topiramate group. The transient 
blurring of vision of 2 (6.6%) patients was recorded in 
the topiramate group and the dose was 50 mg/day. 
Visual acuity was gradually restored two days after 
the drug was discontinued. Other adverse effects of 
the two drugs are as given in Table 2. Oswestry 
disability index was 49.2 + 18.3 pre-drug and post-
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drug 41 + 16.4 for pregabalin (p<0.01), while it was 
43.6 + 37.9 pre-drug and 37.9 + 17.3 post drug (p 
<0.01) for topiramate group as given in Figure 1.  







Age 41.1 ± 12.4 41.6 ± 14.6 
Gender 
Male 24 (80%) 24 (80%) 
Female 6 (20%) 6 (20%) 
Marital Status 
Married  2 (6.7%) 3 (10%) 
Single 28 (93.3%) 27 (90%) 
Work Status 
Strenuous 15 (50%) 12 (40%) 
Non Strenuous 15 (50%) 18 (60%) 
Oswestry Disability Index 
Pre Drug 49.2 + 18.31 43.6 + 17.6 
 
Table 2: Adverse effects of both drugs 




Numbness   0 (0%) 3 (10%) 
Peripheral Edema   0 (0%) 7 (23.3%) 
Dizziness   4 (13.3%) 6 (20%) 
Palpitations   2 ( 6.7%) 0 (0%) 
Headache   0 (0 %) 1 (3.3%) 
Blurring of vision   2 (6.7%) 0 (0%) 
Flushing   0 (0%) 3 (10%) 
Memory lapse   0 (0%) 2 (6.7%) 
Vomiting   0 (0%) 1 (3.3%) 
Weight loss   0 (0%) 1 (3.3%) 
None 22 (73%) 14 (46.7%) 
 
 




Radicular pain secondary to lumbar disc degenerative 
disease is one of the most common ailments with 
which patients present to the out-patient Department 
of Neurosurgery.9 There are options of conservative vs 
surgical management of radicular pain due to 
sciatica.10 Surgical intervention does give early pain 
relief in selected patients but over the long-term, both 
have a similar outcome in terms of pain relief.11 
National guidelines are made based on local 
population data.12 All baseline demographic 
parameters were similar in both groups. The mean age 
of our patients of both groups was 41.1 years which is 
in accordance with the mean age of 42-47 years as 
found by Tubach.13 In our study males were more 
common in both groups, 48 out of 60 patients (80% ) 
whereas Konstantinou found females to be more 
common (62.6%) in their study.14 When we studied the 
effect of gender it was not related to disability due to 
radicular pain is sciatica (p= 0.54). Hofstee and others 
did not find gender to be related to radicular pain but 
later research by Peul found that females did have 
more chronic pain and slower recovery as compared to 
males and he attributed that this is related to 
emotional lability and pain coping mechanism.15,16 
Similarly marital status and nature of work were 
statistically unrelated to the Oswestry Disability Index. 
Oswestry Disability Index was the pain assessment 
tool we used in our study. It is a reliable gauge applied 
to evaluate the baseline and response of treatment in 
patients of radicular pain such as sciatica.17,18 
Pregabalin is a commonly used drug for radicular pain 
and in our study, it statistically better pain outcome in 
Oswestry Disability Index improvement i.e. 49.2 + 18.3 
before drug improved to 41 + 16.4 for pregabalin 
(p<0.01). Topiramate when given to patients had a 
similar response as 43.6 + 17.6 pre-drug vs 37.9 + 17.3 
post drug (p <0.01). Khoromi compared topiramate to 
placebo for chronic lumbar radicular pain and found a 
significant pain-relieving effect of the drug (p< 
0.005).19 Topiramate had less number of patients 
without side effects as compared to pregabalin, 22 
(73%) vs 14 (46.7%). Visual blurring in two patients of 
the topiramate group was a worrisome finding as 
patients had to discontinue the drug for reversal of its 
effect. Except for visual problem topiramate was well 
tolerated. Mathieson et al in their study found out that 
pregabalin when compared with placebo its side 
effects to be significantly high.20 Thus the topiramate 
though as effective as pregabalin in relieving pain is a 
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better drug as patients would be more compliant due 
to fewer side effects. 
The limitation of the study is that a longer follow-up 
will give information about compliance and the late 
side effects of the drugs if any. Efficacy on quality of 
life and return to work requires different parameter 
assessment. Future studies can focus on the 
relationship of response to higher doses of two drugs 
and whether a specific drug is more effective with any 
specific radiological abnormalities of disc degeneration 




Both pregabalin and topiramate are effective for pain 
relief in patients with radicular pain secondary to disc 
degenerative disease. Topiramate is a viable 
alternative for pain management with fewer side 
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